Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis

Table 2 Individual patient data of disease extent, CAI scores pre and post infliximab, steroid usage and therapeutic immunomodulation (therapy > 8 wk at ≥ 1.5 mg/kg of 6-MP) at time of infliximab and time to colectomy

	Sex	Age at diagnosis	Age at infliximab	Disease extent	CAI at infliximab	CAI at 8 wk	On steroids IV or oral	Therapeutic immuno-modulation	Response to infliximab	Time to surgery (mo)
1	F	37	59	Pan Colitis	14	4	Intolerant	No	Complete
2	M	25	26	Pan Colitis	14	0	IV	No	Complete
3	F	28	28	Pan Colitis	11	N/A	IV	No	Partial	1
4	F	45	49	Pan Colitis	14	4	IV	No	Complete
5	F	54	54	Pan Colitis	20	6	IV	No	Partial
6	M	24	28	Pan Colitis	13	4	IV	No	Complete
7	F	22	22	Pan Colitis	11	6	IV	No	Partial
8	M	17	18	Pan Colitis	13	0	Oral	No	Complete	26
9	M	56	58	Proctitis	12	11	Oral	Yes	Nil	8
10	M	54	55	Left sided	15	N/A	Oral	Yes	Nil	< 1
11	M	32	40	Pan Colitis	10	6	Oral	Yes	Partial	12
12	M	25	31	Pan Colitis	16	3 (on steroids)	Oral	Yes	Partial	5
13	M	27	28	Pan Colitis	14	9	Oral	Yes	Partial	9
14	M	32	38	Pan Colitis	8	3 (on steroids)	Oral	Yes	Partial	9
15	M	56	40	Pan Colitis	13	1	Oral	Yes	Complete	6